(SBRA) Sabra Healthcare REIT - Ratings and Ratios
Skilled Nursing, Senior Housing, Behavioral Health, Specialty Hospitals
SBRA EPS (Earnings per Share)
SBRA Revenue
Description: SBRA Sabra Healthcare REIT
Sabra Healthcare REIT Inc (NASDAQ:SBRA) is a healthcare-focused real estate investment trust with a diverse portfolio of 364 properties across the United States and Canada, comprising skilled nursing facilities, senior housing communities, behavioral health facilities, and specialty hospitals. The companys investment portfolio also includes loans receivable, preferred equity investments, and investments in unconsolidated joint ventures.
As a Health Care REIT, Sabras performance is closely tied to the demand for healthcare services and the overall condition of the healthcare industry. Key performance indicators (KPIs) to watch include occupancy rates, revenue per available bed/unit, and same-store sales growth. With 37,075 beds/units across its portfolio, Sabras scale provides a competitive advantage in negotiating with operators and accessing capital.
From a financial perspective, Sabras dividend yield, funds from operations (FFO) per share, and adjusted FFO per share are important metrics to monitor. The companys debt-to-equity ratio, interest coverage ratio, and capitalization rate are also crucial in assessing its financial health and ability to service its debt. A review of Sabras financial statements reveals a market capitalization of $4.3 billion, with a price-to-earnings ratio of 30.12 and a forward price-to-earnings ratio of 8.71, indicating a relatively stable earnings profile.
To further evaluate Sabras investment potential, it is essential to analyze its portfolios quality, tenant/operator creditworthiness, and lease expirations. The companys exposure to different healthcare segments, geographic regions, and payor mixes (e.g., Medicare, Medicaid, private pay) also warrants examination. By examining these factors, investors can better understand Sabras growth prospects, risk profile, and potential for long-term returns.
SBRA Stock Overview
| Market Cap in USD | 4,479m |
| Sub-Industry | Health Care REITs |
| IPO / Inception | 2002-04-02 |
SBRA Stock Ratings
| Growth Rating | 53.6 |
| Fundamental | 69.1% |
| Dividend Rating | 65.2 |
| Rel. Strength | 21.3 |
| Analysts | 3.93 of 5 |
| Fair Price Momentum | 20.09 USD |
| Fair Price DCF | 28.85 USD |
SBRA Dividends
| Dividend Yield 12m | 8.44% |
| Yield on Cost 5y | 15.02% |
| Annual Growth 5y | -2.33% |
| Payout Consistency | 89.7% |
| Payout Ratio | 1.6% |
SBRA Growth Ratios
| Growth Correlation 3m | 65.4% |
| Growth Correlation 12m | 44.3% |
| Growth Correlation 5y | 61.2% |
| CAGR 5y | 13.06% |
| CAGR/Max DD 5y | 0.36 |
| Sharpe Ratio 12m | 2.23 |
| Alpha | 15.47 |
| Beta | 0.301 |
| Volatility | 22.04% |
| Current Volume | 2862.9k |
| Average Volume 20d | 2561.8k |
| Stop Loss | 17.9 (-3%) |
| Signal | 0.00 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (182.3m TTM) > 0 and > 6% of Revenue (6% = 44.0m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 0.75pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -206.0% (prev 67.57%; Δ -273.6pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 338.8m > Net Income 182.3m (YES >=105%, WARN >=100%) |
| Net Debt (1.67b) to EBITDA (475.4m) ratio: 3.50 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (240.9m) change vs 12m ago 3.07% (target <= -2.0% for YES) |
| Gross Margin 68.71% (prev 50.51%; Δ 18.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 13.73% (prev 12.65%; Δ 1.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.70 (EBITDA TTM 475.4m / Interest Expense TTM 112.2m) >= 6 (WARN >= 3) |
Altman Z'' -3.42
| (A) -0.28 = (Total Current Assets 250.2m - Total Current Liabilities 1.76b) / Total Assets 5.33b |
| (B) -0.36 = Retained Earnings (Balance) -1.91b / Total Assets 5.33b |
| (C) 0.06 = EBIT TTM 303.3m / Avg Total Assets 5.34b |
| (D) -0.73 = Book Value of Equity -1.91b / Total Liabilities 2.62b |
| Total Rating: -3.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.11
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 3.93% = 1.96 |
| 3. FCF Margin 46.22% = 7.50 |
| 4. Debt/Equity 1.56 = 1.39 |
| 5. Debt/Ebitda 8.92 = -2.50 |
| 6. ROIC - WACC 1.85% = 2.32 |
| 7. RoE 6.69% = 0.56 |
| 8. Rev. Trend 91.78% = 4.59 |
| 9. Rev. CAGR 10.35% = 1.29 |
| 10. EPS Trend data missing |
| 11. EPS CAGR 48.20% = 2.50 |
What is the price of SBRA shares?
Over the past week, the price has changed by +0.24%, over one month by +1.93%, over three months by +7.47% and over the past year by +23.76%.
Is Sabra Healthcare REIT a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SBRA is around 20.09 USD . This means that SBRA is currently overvalued and has a potential downside of 8.83%.
Is SBRA a buy, sell or hold?
- Strong Buy: 6
- Buy: 1
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SBRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20 | 8.3% |
| Analysts Target Price | 19.6 | 6.1% |
| ValueRay Target Price | 21.5 | 16.4% |
Last update: 2025-08-09 02:51
SBRA Fundamental Data Overview
CCE Cash And Equivalents = 95.2m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 24.2597
P/E Forward = 8.7108
P/S = 6.1025
P/B = 1.6281
P/EG = 3.15
Beta = 0.823
Revenue TTM = 733.0m USD
EBIT TTM = 303.3m USD
EBITDA TTM = 475.4m USD
Long Term Debt = 2.48b USD (from longTermDebt, last quarter)
Short Term Debt = 1.76b USD (from shortTermDebt, last quarter)
Debt = 4.24b USD (Calculated: Short Term 1.76b + Long Term 2.48b)
Net Debt = 1.67b USD (from netDebt column, last quarter)
Enterprise Value = 8.62b USD (4.48b + Debt 4.24b - CCE 95.2m)
Interest Coverage Ratio = 2.70 (Ebit TTM 303.3m / Interest Expense TTM 112.2m)
FCF Yield = 3.93% (FCF TTM 338.8m / Enterprise Value 8.62b)
FCF Margin = 46.22% (FCF TTM 338.8m / Revenue TTM 733.0m)
Net Margin = 24.87% (Net Income TTM 182.3m / Revenue TTM 733.0m)
Gross Margin = 68.71% ((Revenue TTM 733.0m - Cost of Revenue TTM 229.4m) / Revenue TTM)
Tobins Q-Ratio = -4.51 (set to none) (Enterprise Value 8.62b / Book Value Of Equity -1.91b)
Interest Expense / Debt = 0.65% (Interest Expense 27.5m / Debt 4.24b)
Taxrate = 0.79% (from yearly Income Tax Expense: 1.00m / 127.7m)
NOPAT = 300.9m (EBIT 303.3m * (1 - 0.79%))
Current Ratio = 0.14 (Total Current Assets 250.2m / Total Current Liabilities 1.76b)
Debt / Equity = 1.56 (Debt 4.24b / last Quarter total Stockholder Equity 2.71b)
Debt / EBITDA = 8.92 (Net Debt 1.67b / EBITDA 475.4m)
Debt / FCF = 12.51 (Debt 4.24b / FCF TTM 338.8m)
Total Stockholder Equity = 2.72b (last 4 quarters mean)
RoA = 3.42% (Net Income 182.3m, Total Assets 5.33b )
RoE = 6.69% (Net Income TTM 182.3m / Total Stockholder Equity 2.72b)
RoCE = 5.83% (Ebit 303.3m / (Equity 2.72b + L.T.Debt 2.48b))
RoIC = 5.83% (NOPAT 300.9m / Invested Capital 5.17b)
WACC = 3.97% (E(4.48b)/V(8.72b) * Re(7.12%)) + (D(4.24b)/V(8.72b) * Rd(0.65%) * (1-Tc(0.01)))
Shares Correlation 5-Years: 100.0 | Cagr: 1.15%
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.95% ; FCFE base≈323.4m ; Y1≈338.8m ; Y5≈394.4m
Fair Price DCF = 28.85 (DCF Value 6.92b / Shares Outstanding 239.8m; 5y FCF grow 5.11% → 3.0% )
Revenue Correlation: 91.78 | Revenue CAGR: 10.35%
Revenue Growth Correlation: -9.88%
EPS Correlation: N/A | EPS CAGR: 48.20%
EPS Growth Correlation: 55.98%
Additional Sources for SBRA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle